Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Inovalon is a health information services business based in the US. Inovalon stocks (INOV.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $32.8 – an increase of 379.79% over the previous week. Inovalon employs 1,836 staff and has a trailing 12-month revenue of around $749.6 million.
|Latest market close||$197.00|
|52-week range||$23.18 - $41.06|
|50-day moving average||$40.74|
|200-day moving average||$34.83|
|Wall St. target price||$41.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.34|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-01-18)||N/A|
|1 month (2021-12-25)||N/A|
|3 months (2021-10-29)||382.96%|
|6 months (2021-07-29)||419.93%|
|1 year (2021-01-29)||707.38%|
|2 years (2020-01-29)||864.27%|
|3 years (2019-01-29)||1,335.86%|
|5 years (2017-01-27)||1,643.36%|
Valuing Inovalon stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inovalon's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Inovalon's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 123x. In other words, Inovalon shares trade at around 123x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Inovalon's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Inovalon's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Inovalon's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $219.6 million.
The EBITDA is a measure of a Inovalon's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$749.6 million|
|Operating margin TTM||13.8%|
|Gross profit TTM||$499.7 million|
|Return on assets TTM||3.31%|
|Return on equity TTM||7.16%|
|Market capitalisation||$6.4 billion|
TTM: trailing 12 months
We're not expecting Inovalon to pay a dividend over the next 12 months.
Over the last 12 months, Inovalon's shares have ranged in value from as little as $23.18 up to $41.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovalon's is 0.5288. This would suggest that Inovalon's shares are less volatile than average (for this exchange).
Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, an integrated, real-time cloud native platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities. In addition, it offers advisory, implementation, and support services. The company serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. Its platforms include information of data pertaining to approximately one million physicians; 574,000 clinical facilities; and approximately 332 million individuals and 61 billion medical events.
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Use Go Auto to shop for new or used vehicles from multiple dealerships, with no hidden fees and access to bad credit financing.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.